[The reaction of the T-immunity system in patients with malignant skin melanoma and stomach cancer to active nonspecific immunotherapy].
Changes in E-receptor-bearing T-lymphocyte level (total and that of active T-lymphocytes) were studied in peripheral blood and resected material obtained from skin malignant melanoma and gastric cancer patients treated with rigvir, an original immunomodulator of the viral origin. Injection of rigvir into peripheral blood was followed by an increase in active T-lymphocyte level and stimulated their migration into tumor. The latter was determined by stage and rate of tumor advancement.
Glinkina
L S
LS
Bruvere
R Zh
RZh
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D004341:Drug Evaluation; D029822:Enterovirus B, Human; D006801:Humans; D016233:Immunotherapy, Active; D007958:Leukocyte Count; D008545:Melanoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D012397:Rosette Formation; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D013274:Stomach Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology*; D013997:Time Factors
D000276:Adjuvants, Immunologic
Reaktsiia T-sistemy immuniteta bol'nykh zlokachestvennoĭ melanomoĭ kozhi i rakom zheludka na aktivnuiu nespetsificheskuiu immunoterapiiu.